These latest applications will be added to Ziosoft's suite of applications for a robust cardiac tool set for the market.
Redwood City, Calif. (PRWEB) April 7, 2009
Ziosoft®, Inc., http://www.ziosoftinc.com a leader in advanced visualization and analysis software for medical imaging, today announced that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) to market two additional applications for use with the Ziostation thin-client system.
These applications enhance the productivity and diagnostic capability of physicians when evaluating patients' heart health. Both the cardiac function analysis and calcium scoring applications can be accessed throughout the enterprise on the Ziostation thin-client system to provide physicians with improved efficiency and real-time collaboration when assessing results from a CT cardiac scan.
The calcium scoring application is used by physicians to help determine whether a patient may be at increased risk for coronary artery disease. Ziosoft's calcium scoring application features valuable tools for the clinician such as concurrent reading of the calcium analysis adjacent to the original data set, which allows for efficient and precise analysis of data. The cardiac function application enables physicians to conduct a cardiac functional assessment and includes Ziosoft's unique tools such as automatic left ventricle segmentation, peak filling rate (PFR) and peak ejection rate (PER) in addition to the standard functional assessment calculations. The cardiac function application also includes the capability to automatically generate "bulls-eye" maps and a time volume graph to aid in the physician's evaluation.
According to the National Center for Health Statistics (NCHS) every year since 1900, except 1918, cardiovascular disease accounted for more deaths than any other single cause or group of causes of death in the United States. Nearly 2,400 Americans die of cardiovascular disease each day, an average of one death every 37 seconds. These new applications from Ziosoft will contribute to more efficient interpretation and improved communication of test results, leading to enhanced quality of care for patients.
"We are proud of our long history of developing software applications which aid physicians in evaluating diseases" said Kazuhiko Matsumoto, Ziosoft's chief executive officer. "These latest applications will be added to Ziosoft's suite of applications for a robust cardiac tool set for the market."
About Ziosoft Inc.:
Ziosoft, Inc. is a recognized leader in networked advanced visualization and analysis software to benefit physicians, patients, and healthcare specialists. Founded in 1998, Ziosoft is the leading independent advanced visualization company in Japan with over 1800 installed systems.
Ziosoft is dedicated to providing intelligent and intuitive clinical tools across the enterprise. Ziosoft is a privately held company with locations in Redwood City, CA, Brussels, Belgium, and Tokyo, Japan. For more information, please visit http://www.ziosoftinc.com.
Ziosoft and Ziostation are registered trademarks of Ziosoft Inc.